Sarepta Therapeutics Company

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-based therapeutics for the treatment of rare and infectious diseases. The company is primarily focused on rapidly advancing the development of its potentially disease modifying duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen. Sarepta Therapeutics was founded on July 22, 1980 and is headquartered in Cambridge, MA.